A mobile tool to help patients with urothelial carcinoma assess their quality of life
'UROLIFE': a Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma
This study is testing a new mobile app to help patients with urothelial carcinoma track their quality of life and make better decisions about their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS San Raffaele Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Milan, Italy) |
| Trial ID | NCT06982794 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather insights from patients diagnosed with urothelial carcinoma to inform the development of a web app designed to enhance their quality of life assessment and monitoring. Participants, who are candidates for systemic treatments or already undergoing treatment, will complete questionnaires to identify useful content and tools for the app. The goal is to empower patients by improving their understanding of urothelial carcinoma and its treatment options, ultimately facilitating better decision-making. The study focuses on patient-directed input to ensure the app meets their needs effectively.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a histological diagnosis of urothelial carcinoma who are candidates for systemic treatment.
Not a fit: Patients who do not possess a mobile device or are unwilling to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could significantly enhance the quality of life for patients with urothelial carcinoma by providing tailored educational resources and monitoring tools.
How similar studies have performed: While there have been various studies focusing on patient education and quality of life in cancer care, this specific approach using a mobile tool for urothelial carcinoma is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * histological diagnosis of urothelial carcinoma; * ≥ 18 years old, * candidate for systemic treatment with chemotherapy, immune-checkpoint inhibitors, antibody-drug conjugates, or target therapy (patients can be enrolled also if the treatment has started), * possession of a mobile device (e.g., smartphone or personal computer) with the physical and psychological ability to use mobile devices, * understanding and speaking the Italian language, * ability to sign an informed consent. Exclusion Criteria: * not possession of a mobile device, * unwillingness to give informed consent.
Where this trial is running
Milan, Italy
- IRCCS San Raffaele — Milan, Italy, Italy (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.